Chi-Med Initiates FRUTIGA, a Phase III Trial of Fruquintinib in Second-Line Gastric Cancer Tue, 31 Oct 2017 07:20:00 +0000 Hutchison China MediTech Limited has initiated FRUTIGA, a pivotal Phase III clinical trial of fruquintinib in combination with paclitaxel for the treatment in advanced gastric or gastroesophageal junction adenocarcinoma patients in China.
China cancer specialist Chi-Med plans $262 mln share offering Wed, 25 Oct 2017 06:42:03 +0000 China-based cancer and immunology drug specialist Hutchison China MediTech, or Chi-Med, said it aimed to offer $262 million of American Depositary Shares, subject to market conditions, to help fund development ...
Chi-Med Announces Proposed Offering of ADSs Tue, 24 Oct 2017 20:31:00 +0000 Hutchison China MediTech Limited announced today that it intends to offer, subject to market and other conditions, US$262.0 million of American Depositary Shares , each representing one-half of one ordinary share, par value US$1.00 each of Chi-Med , on the Nasdaq Global Select Market .
Edison Issues Update on Hutchison China MediTech (HCM) Wed, 18 Oct 2017 15:56:00 +0000 LONDON, UK / ACCESSWIRE / October 18, 2017 / Data presented at the World Conference on Lung Cancer (WCLC) on combination approaches to treat resistant EGFR-driven non-small cell lung cancer (NSCLC) highlight ...
Chi-Med and AstraZeneca’s Savolitinib Shows Encouraging Clinical Activity in Second-Line EGFR Mutation-Positive Lung Cancer with MET-Amplification Tue, 17 Oct 2017 06:00:00 +0000 Hutchison China MediTech Limited and AstraZeneca PLC today presented preliminary safety and clinical activity data of savolitinib when given in combination with either Tagrisso® or Iressa® in two Phase Ib/II proof-of-concept trials conducted in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer with MET-amplification who had progressed following first-line treatment ...
Hutchison China MediTech: Appointment of Director Thu, 12 Oct 2017 06:52:00 +0000 Hutchison China MediTech Limited today announces that Professor Mok, Shu Kam Tony has been appointed as Independent Non-Executive Director and member of the Technical Committee with effect from October 12, 2017.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.